The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

IU cancer center researcher leads first-in-human multiple myeloma study with 90.5% response rate

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

In a first-in-human clinical trial for patients with relapsed multiple myeloma, led by researchers at Indiana University Melvin and Bren Simon Comprehensive Cancer Center, patients treated with higher doses of the immunotherapy called REGN5459 resulted in a 90.5% overall response rate. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Carvykti extended OS in r/r MM vs standard therapies in phase III trial

Long-term results from the phase III CARTITUDE-4 study show a single infusion of Carvykti (ciltacabtagene autoleucel) significantly extended overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, reducing the risk of death by 45% versus standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account